RT Journal Article
SR Electronic
T1 Etomidate Suppresses Invasion and Migration of Human A549 Lung Adenocarcinoma Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 215
OP 223
DO 10.21873/anticanres.13100
VO 39
IS 1
A1 CHIN-NAN CHU
A1 KING-CHUEN WU
A1 WAI-SHAN CHUNG
A1 LI-CHENG ZHENG
A1 TA-KUO JUAN
A1 YUNG-TING HSIAO
A1 SHU-FEN PENG
A1 JUNG-LONG YANG
A1 YI-SHIH MA
A1 RICK SAI-CHUEN WU
A1 JING-GUNG CHUNG
YR 2019
UL http://ar.iiarjournals.org/content/39/1/215.abstract
AB Background/Aim: Etomidate, an intravenous anesthetic, has been shown to have anticancer effects, including induction of cell-cycle arrest and apoptosis. However, to our knowledge, there are no reports about the anti-metastasis effects of etomidate on A549 human lung adenocarcinoma cells. Materials and Methods: The cell viability, cell adhesion, gelatin zymography assay, transwell migration and invasion assay, and western blotting analysis were used to investigate the effects of etomidate on A549 cells. Results: In our study, etomidate showed low cytotoxicity, inhibited cell adhesion, and suppressed the migration and invasion in A549 cells. The activity of matrix metallopeptidase 2 (MMP2) was reduced by 48 h treatment of etomidate. Results of western blotting analysis indicated that etomidate down-regulated the expression of protein kinase C, MMP7, MMP1, MMP9, and p-p-38, but up-regulated that of RAS, phosphoinositide 3-kinase, and phosphor-extracellular-signal related kinase after 24 and 48 h treatment, in A549 cells. Conclusion: Etomidate suppressed the migration and invasion of lung adenocarcinoma A549 cells via inhibiting the expression of MMP1, MMP2, MMP7 and MMP9, and provides potential therapeutic targets for lung cancer treatment.